13-Dec-2024
Craig-Hallum Releases a Buy Rating on Ligand Pharma (LGND)
TipRanks (Wed, 11-Dec 8:46 AM ET)
Ligand Pharma (LGND) Receives a Buy from Oppenheimer
TipRanks (Wed, 11-Dec 7:46 AM ET)
RBC Capital Releases a Buy Rating on Ligand Pharma (LGND)
TipRanks (Wed, 11-Dec 6:38 AM ET)
TipRanks (Wed, 11-Dec 6:16 AM ET)
Ligand Hosts 2024 Investor and Analyst Day and Introduces 2025 Guidance
Business Wire (Tue, 10-Dec 9:00 AM ET)
Ligand to Present at Stifel 2024 Healthcare Conference
Business Wire (Thu, 14-Nov 8:00 AM ET)
Ligand Reports Third Quarter 2024 Financial Results and Raises 2024 Guidance
Business Wire (Thu, 7-Nov 7:00 AM ET)
Ligand to Host Investor and Analyst Day on December 10, 2024 in Boston
Business Wire (Fri, 1-Nov 8:01 AM ET)
Ligand to Report Third Quarter 2024 Financial Results on November 7, 2024
Business Wire (Wed, 23-Oct 4:01 PM ET)
Palvella Therapeutics Appoints Matthew E. Korenberg as Chief Financial Officer
Globe Newswire (Thu, 17-Oct 7:30 AM ET)
Ligand Pharmaceuticals Inc is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material.
Ligand Pharmaceuticals trades on the NASDAQ stock market under the symbol LGND.
As of December 13, 2024, LGND stock price climbed to $116.91 with 101,890 million shares trading.
LGND has a beta of 1.29, meaning it tends to be more sensitive to market movements. LGND has a correlation of 0.16 to the broad based SPY ETF.
LGND has a market cap of $2.21 billion. This is considered a Mid Cap stock.
Last quarter Ligand Pharmaceuticals reported $52 million in Revenue and $1.84 earnings per share. This beat revenue expectation by $11 million and exceeded earnings estimates by $.49.
In the last 3 years, LGND traded as high as $164.84 and as low as $49.24.
The top ETF exchange traded funds that LGND belongs to (by Net Assets): IJR, IWM, VTI, VB, VBR.
LGND has outperformed the market in the last year with a return of +85.7%, while the SPY ETF gained +31.7%. In the last 3 month period, LGND beat the market returning +14.5%, while SPY returned +8.4%. However, in the most recent 2 weeks LGND has underperformed the stock market by returning -4.6%, while SPY returned +0.9%.
LGND support price is $109.83 and resistance is $117.19 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that LGND shares will trade within this expected range on the day.